ASSESSING THE EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS

Abstract

Background: Smoking remains a leading global public health challenge, responsible for significant morbidity and mortality, particularly through its strong association with lung cancer and other chronic diseases. Despite widespread awareness of its harmful effects, cessation rates remain suboptimal, necessitating the development and evaluation of effective intervention strategies. 

Methods and Materials: This study synthesizes evidence from systematic reviews and clinical research on smoking cessation interventions, including pharmacological treatments such as nicotine replacement therapy (NRT), varenicline, and e-cigarettes, as well as behavioural interventions like counselling and structured support programs. It also examines implementation strategies within primary care, hospital, and community-based settings, alongside barriers affecting both healthcare providers and patients. 

Results: Findings indicate that combined approaches integrating pharmacological and behavioural interventions yield the highest cessation success rates, reaching up to 24% annually, compared to significantly lower rates in unassisted attempts. Pharmacological combinations, particularly NRT with varenicline or e-cigarettes, demonstrated enhanced effectiveness in reducing cravings. Behavioural strategies, including intensive counselling and personalized support, further improved outcomes. However, implementation remains hindered by constraints such as limited time, insufficient training, financial barriers, and patient-related challenges including fear of withdrawal and relapse. 

Conclusion: Smoking cessation interventions are effective but underutilized due to systemic and individual barriers. Optimizing their implementation through improved healthcare infrastructure, increased funding, and tailored patient support is essential to enhance cessation outcomes and reduce the global burden of tobacco use.